Position in LYEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$387,037
New position
Shares Held
19,294
first reported quarter
Ownership
0.083%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0%
Shared 100%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Squarepoint Ops LLC holds $1,094,861,392 across 233 Biotechnology names. LYEL ranks #157 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
426,723 | $141,189,839 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
162,814 | $125,796,608 | |
| 3 | RPRX |
Royalty Pharma plc
|
1,349,516 | $64,736,282 | |
| 4 | IONS |
Ionis Pharmaceuticals Inc
|
695,276 | $52,208,274 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
556,324 | $41,312,620 | |
| 6 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
52,884 | $27,683,187 | |
| 7 | ARQT |
Arcutis Biotherapeutics, Inc.
|
1,103,490 | $25,998,224 | |
| 8 | FOLD |
AMICUS THERAPEUTICS, INC.
|
1,705,829 | $24,666,287 |
All Filings in LYEL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $387,037 | 19,294 | Shares | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||